NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma

BACKGROUND: Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival in recurrent glioblastoma (rGBM). The angiopoiein (Ang)-TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase II, double-blinded, placebo-controlled trial of be...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y, Gerstner, Elizabeth R, Reardon, David A, Aldape, Kenneth D, deGroot, John F, Pan, Edward, Raizer, Jeffrey J, Kim, Lyndon J, Chmura, Steven J, Robins, H Ian, Connelly, Jennifer M, Battiste, James D, Villano, John L, Wagle, Naveed, Merrell, Ryan T, Wendland, Merideth M, Mehta, Minesh P
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245544/
https://ncbi.nlm.nih.gov/pubmed/32154928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32811
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky